IX BIOPHARMA LTD.
(Company Registration No. 200405621W)
(Incorporated in the Republic of Singapore)

PROPOSED RENOUNCEABLE NON-UNDERWRITTEN RIGHTS ISSUE OF UP TO 48,814,711 NEW ORDINARY SHARES IN THE CAPITAL OF IX BIOPHARMA LTD.

- RECEIPT OF LISTING AND QUOTATION NOTICE

---

*Unless otherwise defined, all capitalised terms herein shall have the same meanings as in the Company's announcement dated 8 June 2021 in relation to the Rights Issue (the "**Earlier Announcement**").*

1. INTRODUCTION

The Board of Directors (the "**Board**") of iX Biopharma Ltd. (the "**Company**") refers to the Earlier Announcement.

2. LISTING AND QUOTATION NOTICE

2.1 Further to the Earlier Announcement, the Board is pleased to announce that the Company has on 18 June 2021, received the listing and quotation notice (the "**LQN**") from the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") in relation to the listing and quotation of up to 48,814,711 Rights Shares at an issue price of S$0.20 per Rights Share, subject to compliance with the SGX-ST's listing requirements.

2.2 Please note that the LQN is not to be taken as an indication of the merits of the Rights Issue, the Rights Shares, the Company, its subsidiaries and their securities.

3. OFFER INFORMATION STATEMENT

The Offer Information Statement in relation to the Rights Issue will be despatched or disseminated to Shareholders in due course, and appropriate announcements in relation to its lodgement and despatch or dissemination will be made.

4 CAUTIONARY STATEMENT

Shareholders and potential investors are advised to exercise caution when dealing or trading in the Shares. The completion of the Rights Issue are subject to certain conditions. As at the date of this announcement, there is no certainty or assurance that the Rights Issue will be completed or that no changes will be made to the terms thereof. The Company will make the necessary announcements when there are further developments. Shareholders and potential investors are advised to read this announcement and any further announcements by the Company carefully. Shareholders and potential investors should consult their stockbrokers, bank managers, solicitors, accountants, tax advisers or other professional advisers if they have any doubt about the actions they should take.

BY ORDER OF THE BOARD

Lee Wei Hsiung / Wang Shin Lin, Adeline
Company Secretaries

21 June 2021

This announcement has been prepared by the Company and its contents have been reviewed by the Company's Sponsor, UOB Kay Hian Private Limited (the "**Sponsor**"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Lance Tan, Senior Vice President at 8 Anthony Road, #01-01, Singapore 229957, telephone: (65) 6590 6881.